AIMS: Cysteamine is used to reduce tissue cystine content in patients suffering from nephropathic cystinosis. The objectives of the current study were to investigate pharmacokinetics and pharmacodynamics of cysteamine bitartrate in children and young adults with nephropathic cystinosis. METHODS:Cysteamine bitartrate was administered to 11 cystinosis patients at their regular dose level in a single-dose, open-label, steady-state study. Blood samples were collected and analysed for plasma cysteamine and white blood cell cystine content and pharmacokinetic and pharmacodynamic parameters estimated by NONMEM analysis using a linked pharmacokinetic-pharmacodynamic model. RESULTS:Cysteamine was rapidly cleared from the plasma (mean CL/F = 32.3 ml min(-1) kg(-1), range = 17.3-52.2), appeared to be extensively distributed (mean Vss/F = 15.1 l, range 2.7-32.3) and exhibited a mean Tmax of 1.4 h. White blood cell cystine content post-dosing was significantly decreased compared with pre- and post-dose values (average decrement approximately 47%). A counter-clockwise hysteresis was noted in all patients, suggestive of a lag time (mean Tlag = 0.44 h, range 0.22-0.92) between drug concentration and effect. CONCLUSIONS: The results of this study establish that cysteamine is rapidly cleared from the plasma but that an every 6 h dosing interval adequately maintains white blood cell cystine content below the target of 1 nmol cystine per mg protein.
RCT Entities:
AIMS: Cysteamine is used to reduce tissue cystine content in patients suffering from nephropathic cystinosis. The objectives of the current study were to investigate pharmacokinetics and pharmacodynamics of cysteamine bitartrate in children and young adults with nephropathic cystinosis. METHODS:Cysteamine bitartrate was administered to 11 cystinosispatients at their regular dose level in a single-dose, open-label, steady-state study. Blood samples were collected and analysed for plasma cysteamine and white blood cell cystine content and pharmacokinetic and pharmacodynamic parameters estimated by NONMEM analysis using a linked pharmacokinetic-pharmacodynamic model. RESULTS:Cysteamine was rapidly cleared from the plasma (mean CL/F = 32.3 ml min(-1) kg(-1), range = 17.3-52.2), appeared to be extensively distributed (mean Vss/F = 15.1 l, range 2.7-32.3) and exhibited a mean Tmax of 1.4 h. White blood cell cystine content post-dosing was significantly decreased compared with pre- and post-dose values (average decrement approximately 47%). A counter-clockwise hysteresis was noted in all patients, suggestive of a lag time (mean Tlag = 0.44 h, range 0.22-0.92) between drug concentration and effect. CONCLUSIONS: The results of this study establish that cysteamine is rapidly cleared from the plasma but that an every 6 h dosing interval adequately maintains white blood cell cystine content below the target of 1 nmol cystine per mg protein.
Authors: J A Schneider; K F Clark; A A Greene; J S Reisch; T C Markello; W A Gahl; J G Thoene; P K Noonan; K A Berry Journal: J Inherit Metab Dis Date: 1995 Impact factor: 4.982
Authors: Elena N Levtchenko; Carin M van Dael; Addy C de Graaf-Hess; Martijn J G Wilmer; Lambertus P van den Heuvel; Leo A Monnens; Henk J Blom Journal: Pediatr Nephrol Date: 2005-10-27 Impact factor: 3.714
Authors: Gundula Min-Oo; Kodjo Ayi; Silayuv E Bongfen; Mifong Tam; Irena Radovanovic; Susan Gauthier; Helton Santiago; Antonio Gigliotti Rothfuchs; Ester Roffê; Alan Sher; Alaka Mullick; Anny Fortin; Mary M Stevenson; Kevin C Kain; Philippe Gros Journal: Exp Parasitol Date: 2010-02-26 Impact factor: 2.011
Authors: Maria Borrell-Pagès; Josep M Canals; Fabrice P Cordelières; J Alex Parker; José R Pineda; Ghislaine Grange; Elzbieta A Bryson; Martine Guillermier; Etienne Hirsch; Philippe Hantraye; Michael E Cheetham; Christian Néri; Jordi Alberch; Emmanuel Brouillet; Frédéric Saudou; Sandrine Humbert Journal: J Clin Invest Date: 2006-04-06 Impact factor: 14.808
Authors: Zygmunt Warzecha; Dagmara Ceranowicz; Artur Dembiński; Piotr Ceranowicz; Jakub Cieszkowski; Atsukazu Kuwahara; Ikuo Kato; Marcin Dembiński; Peter C Konturek Journal: Med Sci Monit Date: 2012-05
Authors: Martijn J Wilmer; Joost P Schoeber; Lambertus P van den Heuvel; Elena N Levtchenko Journal: Pediatr Nephrol Date: 2010-08-24 Impact factor: 3.714